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Introduction: The paclitaxel-coated balloon catheter (DCB) based on the PACCOCATH
technology has yielded angiographic and clinical results superior to drug-eluting stents
(DES) in situations like in-stent restenosis (ISR) and a trend towards superior results in
small coronary vessels and side branches of coronary bifurcations. Using the DCB followed
by cobaltechromium stent (CoCr) deployment or with a reverse sequence may yield
different outcomes in terms of late loss.
Methods: 97 patients with de-novo coronary stenosis (55.6  10.7 years, 79.4% male, 70%,
length: 25 mm, vessel diameter: 2.5e4.0 mm) were randomly treated with the DCB (3 mg/
mm2) followed by a CoCr-stent or stent first and DCB later. Six-month angiographic and
one-year clinical follow-up intention-to-treat analyses were performed.
Results: Angiographic and demographic baseline data was comparable between the two
groups. When comparing balloon first versus stent first technique, the primary outcome
variables were not statistically different for mean in-segment (0.51  0.56 mm vs.
0.36  0.55 mm, p ¼ 0.23) and in-stent (0.52  0.55 mm vs. 0.46  0.52 mm, p ¼ 0.65) late
lumen loss. The lesion related 12-month MACE rates were 5/49 (10.2%) and 2/48 (4.2%)Institute, Okhla Road, New Delhi 110025, India.
(U. Kaul).
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 7 511(p ¼ 0.44). Lesion related thrombotic events occurred in three patients in balloon first and in
one patient in stent first group, two of which were associated with early discontinuation of
continuous dual anti-platelet therapy, two with suboptimal PCI, and one each were per-
formed in a thrombotic lesion and a bifurcation type 1.1.0.
Conclusion: Drug-coated balloon first followed by cobalt chromium stent deployment versus
a reverse sequence is not associated with statistically significantly different 6-month
angiographic or 12-month clinical outcomes.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction two in two distinct coronary arteries. Exclusion criteriaThe paclitaxel-coated balloon catheter (DCB) based on the
PACCOCATH technology has yielded angiographic and clin-
ical results superior to drug-eluting stents (DES) in in-stent
restenosis (ISR) up to 5 years after the procedure1e4 and
trended superior in small vessel coronary artery disease5 and
in the side branches of coronary bifurcations.6 Pathophysio-
logically, these positive results may be explained by delivery
of the antiproliferative agent along the entire treated segment
as opposed to only 15% when deploying a DES.7,8 Hence,
addressing recoil and neointimal growth as causes of reste-
nosis by providing the mechanical stabilization through
placing a new generation bare-metal stent and reducing
neointimal proliferation by delivering the anti-neoplastic
agent paclitaxel by means of a DCB catheter might combine
the advantages of both devices. In bail-out situations of the
PEPCAD I trial, however, the rate of major adverse cardiac
events (MACE) was less favorable.5 Theoretically, the
sequence in which the devices are used may affect the
angiographic and clinical outcome. Consequently, it was
investigated if either dilating the lesion with the DCB first
followed by cobaltechromium stent (CoCr) deployment or by
reversing the sequence would be associated with different
results in native coronary lesions. Six-month angiographic
and one-year clinical follow-up is reported in this paper.2. Methods
The study is a randomized, non-blinded, multi centric study
conducted at 7 Indian cardiology centers. The study was
sponsored by B. Braun Melsungen AG, Vascular Systems,
Berlin, Germany, themanufacturer of the drug-coated balloon
catheter. An independent Clinical Research Organization and
core lab (Clinical Research Institute, Center of Cardiovascular
Diseases, Rotenburg an der Fulda, Germany) took re-
sponsibility for the Quantitative coronary analysis and
compilation of the data.
The study was performed according to the declaration of
Helsinki,World Health Organization and ICMR guidelines. The
protocol was approved by the ethics committees of all the
participating centers. Patients provided written informed
consent prior to enrolment.
Eligible patients were at least 18-year-old, had clinical ev-
idence of stable (CCS class 1e3) or unstable angina (Braunwald
class 1e2, AeC) or objective evidence of ischemia, and
exhibited at least one stenosis in one native coronary artery orcomprised factors such as acute myocardial infarction within
the preceding 48 hours; severe renal insufficiency (GFR
<30 ml/min); hypersensitivity or contraindication to three
months anti-platelet agents; or malignancies with a life ex-
pectancy of less than 3 years. Angiographic inclusion criteria
encompassed lesions from 10 to 25 mm (inclusive) in length,
vessel diameters from 2.5 to 4.0 mm (inclusive), and stenoses
from 70% to less than 100% of the reference lumen diameter.
Exclusion criteria encompassed unprotected left main steno-
sis, bifurcations, and lesions with an originating major side
branch of more than 2 mm in diameter.
2.1. Study devices
The drug-coated coronary angioplasty balloon catheter
(SeQuent Please, B. Braun Melsungen AG, Vascular Systems,
Berlin, Germany) is covered with 3 mg paclitaxel/mm2 of
balloon surface area using iopromide as the hydrophilic
spacer. The balloons used were 14 to 30 mm (inclusive) long
with diameters ranging from 2.5 to 4.0 mm (inclusive). Drug
release is more than 90% upon single balloon inflation.9
The cobaltechromium L605 stent (Coroflex Blue, B. Braun
Melsungen AG, Vascular Systems, Berlin, Germany) is based
on the SeQuent Rapid PTCA Catheter Exchange Technology
and features thin struts of 65 mm (0.0025"), a crossing profile of
0.84 mm (0.033"), and a balloon overhang of <0.5 mm (0.019")
on each side of the stent.
2.2. Interventional procedure
Percutaneous coronary interventions were performed
through the femoral access. Patients were administered
350 mg of aspirin, heparin as an initial bolus of 70e200 IU/kg
body weight adjusted according to the activated clotting time
with a target of 200 to 250 sec, and obtained a loading dose of
300 mg of clopidogrel the day prior to the procedure or 600 mg
immediately before the intervention. Glycoprotein IIb/IIIa
antagonists were administered at the operator’s discretion.
Intracoronary injection of 100 to 200 mg nitroglycerin preceded
baseline angiography of the target vessel in at least two near-
orthogonal views to avoid foreshortening and vessel overlap.
After assessment of the angiographic in- and exclusion
criteria, each eligible patient was randomly assigned by en-
velope to treatment of the target lesion with either of the two
treatment sequences.
Before using either of the drug-eluting devices, pre-dilation
of the target lesion was optional by means of a conventional
Table 1 e Baseline clinical and angiographic data
(intention-to-treat analysis).a
Balloon first
(n ¼ 49)
Stent first
(n ¼ 48)
p
Coronary risk factors
Age 54  11.1
years
57.3  10.1
years
0.14
Male gender 42 (85.7%) 35 (72.9%) 0.19
Diabetes mellitus 14 (28.6%) 14 (29.2%) 0.84
Hyperlipidemia 8 (16.3%) 6 (12.5%) 0.62
Smoking
Current 15 (30.6%) 15 (23.1%) 0.10
Previous 8 (16.3%) 9 (18.8%)
Never 25 (51%) 31 (64.6%)
Hypertension 30 (61.2%) 26 (54.2%) 0.64
Body mass index 25.35 
3.5 kg/m2
25.7  4.8
kg/m2
0.67
Family history of
coronary artery
disease
11 (22.4%) 9 (18.8%) 0.8
Unstable angina 16 (32.7%) 17 (35.4%) 0.77
Coronary artery disease
Single-vessel disease 39 (79.6%) 38 (79.2%) 1.0
Two-vessel disease 9 (18.4%) 9 (18.8%)
Three-vessel disease 1 (2%) 1 (2.1%)
Vessel with target lesion
LAD 24 (41.4%) 20 (35.7%) 0.79
LCx 14 (24.1%) 16 (28.6%)
RCA 20 (34.5%) 20 (35.7%)
Classification of
1st/2nd stenosis
49/9 48/8 0.35/0.20
A 2 (4.1%)/0 5 (10.4%)/1
(12.5%)
B1 29 (59.2%)/7
(77.8%)
23 (47.9%)/3
(37.5%)
B2 18 (36.7%)/2
(22.2%)
20 (41.7%)/4
(50.0%)
Classification of 1st
and 2nd stenoses
combinedb
58 56 0.14
A 2 (3.4%) 6 (10.7%)
B1 36 (62.1%) 26 (46.4%)
B2 20 (32.8%) 24 (42.9%)
a All values are mean  standard deviation or n(%). CAD, coronary
artery disease; RCA, right coronary artery; LCx, left circumflex cor-
onary artery; LAD, left anterior descending coronary artery.
b ACC/AHA task force.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 7512balloon of any brand. The recommended inflation time for the
DCB was 30 sec.10 Post procedure, the vascular sheaths were
removed according to usual hospital practice.
2.3. Quantitative coronary angiography
Angiography was performed before and after all in-
terventions, at 6 months, and when clinically indicated using
identical projections. Quantitative analysis of the images was
performed by an independent core laboratory (Clinical
Research Institute, Rotenburg/ Fulda, Germany) by two oper-
ators. The CAAS II system (Pie Medical, The Netherlands)
served for automated contour detection and quantification
with manual adjustment in obvious cases of machine error.
Measurements included the stented area from shoulder to
shoulder (in-stent) and the total treated area plus 5 mm on
either side (in-segment). Restenosis was defined as a diameter
stenosis of 50%.
2.4. Follow-up and endpoints
All patients received 100 mg aspirin daily scheduled for life.
Clopidogrel (75 mg/day) was administered for a minimum of
threemonths. Patients were subject to clinical observation for
3 years following the index procedure. All endpoints and
adverse events were adjudicated by an independent clinical
events committee.
In-segment late lumen loss, the difference between the
minimal lumen diameter after the procedure and at six
months as evaluated by quantitative coronary angiography,
was the primary endpoint. Secondary endpoints encom-
passed the rate of restenosis and the rate of the combined
clinical events up to 3 years, including stent thrombosis,
target lesion revascularization, myocardial infarction, and
death. Stent thrombosis was defined according to ARC.11
Target-lesion revascularization was defined as percuta-
neous reintervention or coronary artery bypass grafting of
the restenotic target lesion. The decision to perform revas-
cularization was based on symptoms and angiographic
findings at follow-up. Occurrence of myocardial infarction
was assumed if at least two of the following five criteria
were present: chest pain lasting longer than 30 minutes;
electrocardiogram (ECG) diagnostic of acute myocardial
infarction (ST-segment elevation of 0.1 mV in at least two
adjacent ECG leads or the new occurrence of a complete left
bundle-branch block); increase in the level of creatine ki-
nase or its MB isoform of at least three times the upper
normal limit; new, clinically significant Q-waves; and chest
pain necessitating angiography up to 6 hours after onset of
the pain with angiographic evidence of an occluded vessel.
Serious adverse events were defined according to interna-
tional (ICH) guidelines.11
2.5. Statistical analysis
Owing to the lack of even anecdotal predicate data no sample
size estimation could be performed. In line with studies
investigating new indicationswith this DCB, 125 patientswere
planned to have been enrolled in this pilot study during a
period of 6 months starting August 2008.2,5,12,13 Since adefinite endpoint of enrolment was set, only 97 patients could
be enrolled till September 2011.
Data were analyzed as per intention-to-treat. Normally
distributed continuous variables are expressed as
mean  standard deviation. Categorical variables were
compared with the Fisher’s exact test, continuous variables
with the two-sided Student’s t-test or the Welch’s test for
unequal variances. Confidence intervals for the difference
between proportions were calculated with a normal
approximation of the binomial distribution with correction
for continuity (PASW Statistics 18 and BiAS 9.06). Event-free
survival was compared by KaplaneMeier analysis with the
ManteleCox log-rank test constructed by SPSS software,
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 7 513version 15.0. p-values of <0.05 were considered statistically
significant.3. Results
3.1. Patients
Ninety-seven patients (55.6  10.7 years, 79.4% male) were
enrolled in the study between August 2008 and March 2010.
Forty-nine (50.5%) patients were randomly assigned to treat-
ment with the DCB first, while in 48 (49.5%) subjects, the CoCr-Table 2 e Procedural data, angiographic findings at interventio
(intention-to-treat analysis).a
Balloo
(n ¼ 58
Procedural data
Drug-coated balloon
Length 22.5  4
Diameter 2.9  0.3
Maximum inflation pressure 9.67  2
Duration of inflation 35.6  1
Cobalt-chromium stent
Length 18.5  4
Diameter 3  0.4 m
Maximum inflation pressure 13.5  2
Duration of inflation 27  18.
Balloon for pre-dilation
Length 13.2  3
Diameter 2.3  0.5
Maximum inflation pressure 10.5  2
Duration of inflation 23.2  1
Additional stents 1 (1.7%)
Lesion data
Lesion length 12  4.3
Reference diameter 2.8  0.4
Diameter stenosis in-segment before intervention 77.1  9
Diameter stenosis in-segment post intervention 16.2  8
Minimal lumen diameter in-segment before intervention 0.64  0
Minimal lumen diameter in-segment post intervention 2.41  0
Angiographic 6-month follow-up
46 (79.3%
Time of angiographic follow-up 6.8  1.6
Minimal lumen diameter in-segment at follow-up 1.93  0
Diameter stenosis at follow-up 32  20%
Late lumen loss
In-segment 0.51  0
In-stent 0.52  0
Late lumen loss index
In-segment 0.29  0
In-stent 0.29  0
Binary restenosis rate (including occlusion and thrombosis)
In-segment 8/58 (13
In-stent 8 (13.8%
Patterns of in-stent restenosisb
I 3/8 (37.5
II 1/8 (12.5
III 0 (0%)
IV (including thrombus) 4/8 (50.0
a All values are mean  standard deviation or n (%). CI, confidence interv
b Patterns of in-stent restenosis in patients with repeated restenosis at fstent was deployed prior to using the DCB. Demographics,
angiographic and other baseline characteristics of the patients
were comparable between the two groups (Table 1).
3.2. Angioplasty
The procedural success rates were 100% throughout the study
with the DCB crossing all lesions in both groups. The inflation
pressuresof theCo-Crstentweresignificantlyhigher (p¼0.02) in
the balloon first (13.5  2.1 bars) compared to the stent first
(12.3  3.1 bars) group after a longer balloon had been used for
pre-dilation in the balloon first group (13.2  2.3 mm vsn and 6-month angiographic and clinical follow-up
n first
lesions)
Stent first
(n ¼ 56 lesions)
Difference
(95% CI)
p
.7 mm 22.3  5.4 mm 0.19 (1.71 to 2.08) 0.85
8 mm 3  0.4 mm 0.1 (0.25 to 0.05) 0.2
.78 bar 9.4  2.7 bar 0.26 (0.78 to 1.29) 0.62
3.7 sec 33.2  11.7 sec 2.41 (2.55 to 7.36) 0.34
.2 mm 19.4  4.9 mm 0.95 (2.69 to 0.77) 0.28
m 3  0.4 mm 0.01 (0.17 to 0.14) 0.86
.1 bar 12.3  3.1 bar 1.18 (0.16 to 2.2) 0.02
1 sec 23.4  8.6 sec 3.635 (2.35 to 9.63) 0.23
.2 mm 11.9  2.2 mm 1.32 (0.02 to 2.62) 0.047
mm 2.3  0.5 mm 0.05 (0.17 to 0.28) 0.63
.1 bar 9.6  3.1 bar 0.89 (0.44 to 2.2) 0.19
2.8 sec 19.8  7.8 sec 0.34 (2.8 to 9.7) 0.27
2 (3.6%) 0.02 (0.10 to 0.06) 0.98.
mm 12  4.1 mm 0.4 (1.59 to 1.51) 0.96
mm 2.8  0.4 mm 0.02 (0.14 to 0.17) 0.84
.4% 75.2  10.9% 1.91 (1.86 to 5.67) 0.32
.9% 16.9  8.5% 1.63 (3.96 to 2.49) 0.65
.29 mm 0.7  0.32 mm 0.06 (0.17 to 0.05) 0.3
.47 mm 2.37  0.46 mm 0.04 (1.13 to 0.21) 0.63
) 44 (78.6%) 0.01 (0.16 to 0.17) 0.89
months 6.6  1.2 months 0.17 (0.54 to 0.88) 0.64
.7 mm 2.05  0.6 mm 0.12 (0.41 to 0.16) 0.39
32.5  16.8% 0.43 (7.63 to 8.48) 0.92
.56 mm 0.36  0.56 mm 0.15 (0.1 to 0.39) 0.23
.55 mm 0.46  0.52 mm 0.05 (0.18 to 0.29) 0.65
.32 0.2  0.38 0.09 (0.06 to 0.25) 0.22
.31 0.27  0.35 0.03 (0.12 to 0.17) 0.69
.8%) 6 (10.7%) 0.03 (0.11 to 0.17) 0.78
) 6 (10.7%) 0.03 (0.11 to 0.17 0.78
%) 4/6 (66.7%) 0.46
%) 0 (0%)
0 (0%)
%) 2/6 (33.3%)
al.
ollow-up angiography according to the Mehran classification.
Table 3 e One-year MACE rates.
Balloon first Stent first p
Count [n] 49 (50.5%) 48 (49.5%) NA
Missing [n] 1 (2.1%) 4 (8.3%) 0.20
Deaths
Total 2/49 (4.1%) 2/48 (4.2%) 1
Cardiac 1/49 (2.0%) 1/48 (2.1%) 1
Lesion related 0/49 (0%) 0/48 (0%) 1
Non-lesion related 0/49 (0%) 1/48 (2.1%) 1
Unknown 1/49 (2.0%) 0/48 (0%) 1
Non-cardiac (no MACE) 1/49 (2.0%) 1/48 (2.1%) 1
Myocardial infarction
Total 1/49 (2.0%) 1/48 (2.1%) 1
CK-Elevation >3 times
upper normal limit
0/49 (0%) 1/48 (2.1%) 1
MI other than target vessel 1/49 (2.0%) 0/48 (0%) 1
Stent thrombosis with MI
target lesion related
3/49 (6.1%) 1/48 (2.1%) 0.62
PCI or CABG for in-segment
stenosis >50%
2/49 (4.1%)a 1/48 (2.1%)a 1
Total MACE 8/49 (16.3%) 4/48 (8.4%) 0.36
Target lesion related MACE
(cardiac death, myocardial
infarction, revascularization)
5/49 (10.2%) 2/48 (4.2%) 0.44
a Each additional 4 patients withmedical treatment for in-segment
restenosis.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 751411.9 2.2mm, p¼ 0.047). The remaining procedural parameters
were statistically not different between the two treatment se-
quences (Table 2).
Pre-dilation was performed in 30/49 (61.2%) patients in the
DCB first and in 29/48 (60.4%) patients of the stent first group.
A second bare metal stent was required in 2/48 (4.2%) patients
of the stent first group and in 1/49 (2.0%) patients of the
balloon first group.
3.3. Angiographic follow-up
Follow-up angiography after 6.7  1.4 months in 74/97 (76.2%)
patients and 90/114 (78.9%) lesions showed no statistical dif-
ference in the angiographic results, in particular in the pri-
mary outcome parameters of mean late lumen loss in-
segment of 0.51  0.56 mm (balloon first) vs 0.36  0.55 mm
(stent first) (p ¼ 0.23) and in-stent of 0.52  0.55 mm (balloon
first) vs 0.46 0.52mm (stent first) (p¼ 0.65). The QCA findings
at baseline after the procedure and at 6 months are shown in
Fig. 1.
3.4. Clinical follow-up
After one year, for clinical follow-up 48/49 (98.0%) patients
were available in the balloon first group and 44/48 (91.7%) in
the stent first group (p ¼ 0.2). In each group, the two deaths
occurred within the first six months of follow-up. One patient
in each group died of a non-cardiac cause. In the balloon first
group, one patient died at homewith no information available
relative to the target lesion. The cardiac death was not related
to the target lesion in the stent first group (Table 3).
A total of 4 thromboses (all angiographically proven)
occurred during the one-year follow-up, three in the balloon
first and one in the stent first group (Table 4).
The KaplaneMeier estimates of survival free from clinical
events during the 1-year follow-up did not exhibit a statistical
difference between the two treatment sequences (Fig. 2).Fig. 1 e Angiographic patency: cumulative frequency distributio
determined by quantitative coronary angiography (n[ 114 lesio
(pre), post-procedure (post), and at six months (follow-up). Inte4. Discussion
The Paclitaxel DCB based on the PACCOCATH technology has
yielded angiographic and clinical results superior to DES in ISR
up to five years after the procedure1e4 and trended superior in
small vessel coronary artery disease5 and in the side branches
of coronary bifurcations.6 Though centers on two continents
with a large number of operators and a variety of indications
participated in these studies the late lumen loss for DCB stand
alone procedureswas consistently below 0.2mm, indicative ofn of in-segment minimal lumen diameters (MLD)
ns in 97 patients). Balloon first vs stent first; pre-procedure
ntion-to-treat analysis.
Table 4 e Procedural and follow-up information of patients with thrombotic events.
Treatment
group
Time
from
PCI
[days]
Thrombotic risk
factors
Information on index PCI Treatment of
thrombosis
Follow-up
Balloon first 274 DAPT discontinued,
smoking resumed
(20 cigarettes/day)
Stent undersized and
underexpanded
Abciximab and
POBA
At one year follow the patient
was asymptomatic
Balloon first 15 Arterial hypertension,
current smoker,
irregular intake of
DAPT
Balloon and stent both too
short relative to lesion
POBA New in-stent thrombosis after
4 months. No PCI performed
Balloon first 1 None Small hazy spot in proximal
lesion suggestive of a small
thrombus
Abciximab, POBA,
and BMS
No angiographic restenosis
after 6 months
Stent first 6 None Bifurcation 110*. Balloon lead
to dissection type B. Stent
undersized
POBA þ DCB þ BMS No angiographic restenosis
after 4 months
BMS ¼ bare metal stent, DAPT ¼ dual anti-platelet therapy, DCB ¼ drug-coated balloon POBA ¼ plain old balloon angioplasty*.24
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 7 515an easily handled device with reproducible and satisfactory
outcomes.2,5,6,12,13 In some instances, however, a pronounced
elastic recoil or vessel dissection, would necessitate deploy-
ment of a bare metal stent. In addition, theoretically, adding a
bare metal stent might further reduce restenosis owing to the
greater lumen gain post procedure.
The data of the current study seem to refute this hypoth-
esis with the in-segment late lumen loss between
0.5  0.56 mm (balloon first) and 0.36  0.56 mm (stent first)
(95% CI: 0.15 (0.1 to 0.39), p ¼ 0.23). Nonetheless, the differ-
ence of 0.14 mm raises concerns that with a larger number ofFig. 2 e Freedom from stent thrombosis, target lesion revascular
Cox). Intention-to-treat analysis (n [ 97 subjects with n [ 114subjects, the level of significance might have been reached.
The difference for in-stent late lumen loss was much smaller
(0.52 0.55mmvs 0.46 0.52mm, 95%CI 0.05 (0.18 to0.29),
p¼ 0.65) suggesting that theweakest pointmay be the edges of
the stent due to geographical mismatch.
The late lumen lossmeasured in both treatment sequences
are within the range of those of paclitaxel-eluting stents.13e17
However, the in-segment late lumen losses in both treatment
sequences are higher than all of those reported in DCB alone
procedures. These are; however, considerably lower than in
the bail-out situations of the PEPCAD I with 0.62  0.73 mm.5ization, myocardial infarction, and death. Log rank (Mantel-
lesions).
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 1 0e5 1 7516The difference in the late loss observed from the bailout sit-
uation may be due to the different pathology or an ethnic
difference and is purely speculative.
The one-year MACE rates were not statistically different
(balloon first 10.2%, stent first 4.2%, p ¼ 0.44) between the two
treatment sequences. After six months, the lesions appeared
clinically stable with only one event occurring in the stent first
sequence. However, when the balloon was used first, three
thrombotic events occurred, one each within the first hour
after theprocedure,onday15andday274,whilewithstentfirst
one such event was documented on day 6. All of these pro-
cedures were associated with thrombotic risk factors such as
discontinuation of dual anti-platelet therapy or procedural is-
sues including under sizing of the stent (Table 4). The vari-
ability in the brands of clopidogrel used as compared to the
brandused in the other studies of the PEPCADprogram1,5,6,12,13
could have been a factor. Relatively high frequency of smoking
in our subjects with thrombosis could also have contributed
even in presence of aspirin.18 Ethnic factors of clopidogrel
resistance may also have played a causal role as well.19
Aside from these events, target lesion revascularization
(4.1% vs 2.1%), lesion related myocardial infarction (0 vs 2.1%)
or death (0 vs 2.1%) were low and within the range of the 8%e
17.8% reported for paclitaxel-eluting stents.13e17 It is widely
accepted that delivery of the antiproliferative agent along the
entire treated segment as opposed to only 15%whendeploying
a drug-eluting stent is one of several theoretical pathophysio-
logicmechanisms that influence the incidence of restenosis.7,8
There is ample evidence that stents increase the post proce-
dural vascular diameter, themetal scaffolds instigate negative
mechanismsthatultimatelymayoutweigh theirbenefits.Such
effects encompass the inherent effects of any stent such as
increased vascular damage by the force to the vascular wall20
and sustained mechanical irritation21 and the impairment of
vascularmobility.22 Itmay be hypothesized thatwhen theDCB
precedes stent deployment, compression of the vascular wall
by the stent struts may increase the concentration of the
antiproliferative drug to supposedly toxic levels, thus trig-
gering an inflammatory reaction thatmay enhanceneointimal
proliferation and endothelial dysfunction. Moreover, when
using the DCB first, chances for geographic mismatch, identi-
fied as a predictor for restenosis may be higher as opposed to
when using the stent first since in the former the reference
point for stent or balloon placement is missing.5 When stent
deployment precedes DCB dilation then the contact surface
between the balloon and the vessel wall is reduced by around
15% owing to the surface of the stent struts.
A larger study would be more meaningful to substantiate
the findings of this pilot study. Until studies with intravas-
cular ultrasound and the routine careful assessment of the
quality of platelet function are performed, the possible causes
of the thrombotic events will remain at best speculative. It
may thus be appropriate to continue dual anti-platelet ther-
apy for 1 year when a combination of DEB and stent is used
like in the case of a DES.
In conclusion, this study using the DCB based on the
PACCOCATH technology before a CoCr bare metal stent or
with a reversed sequence of stent first did not show a statis-
tical difference neither in the 6-month angiographic nor the
12-month clinical outcome parameters in the treatment ofnative coronary artery stenosis. Both procedural sequences
“stent first” and “balloon first” appear as safe and effective
treatment modalities for native coronary artery stenosis.
These results match favorably with those of paclitaxel-eluting
stents.13e17 The German Consensus Group for “DEB-only”
recommends using this DCB based on the PACCOCATH
technology when stenting needs to be avoided.23 The current
study lends further support to this recommendation since the
option of adding a bare metal stent still remains as a safe and
effective option. However, under sizing and under expansion
of the bare metal stents seem to be important contributing
factors to stent thrombosis and, therefore, must be avoided.5. Study limitations
1. Due to slow recruitment of cases, only 97 patients could be
recruited in the study though the original plan was to
include 125 patients.
2. The angiographic follow-up was possible in only 78% cases
though the clinical follow-up was available in 95% patients.Conflicts of interest
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